Evidence map›Paper›PMID 33185336›Full record

ArticleLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society2021

Impact of Payer Status on Delisting Among Liver Transplant Candidates in the United States.

Krystal L Karunungan, Yas Sanaiha, Roland A Hernandez, Holly Wilhalme, Sarah Rudasill, Joseph Hadaya, Joseph DiNorcia, Peyman Benharash

Open access · greenAbstract read
In one paragraph

Article in Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Health disparities in cirrhosis care and liver transplantation.Nature reviews. Gastroenterology & hepatology · 2025
    Review
  3. Waiting for a Liver Transplant in New Mexico; Understanding the State's Multi-layered Adversity.Journal of community hospital internal medicine perspectives · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Racial Disparity in Liver Transplantation Listing.Journal of the American College of Surgeons · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Krystal L KarununganCardiovascular Outcomes Research Laboratories (CORELAB)Department of Surgery David Geffen School of Medicine at University of California, Los Angeles Los Angeles CA Division of Cardiac Surgery Swedish Medical Center Seattle WA Dumont-UCLA (University of California, Los Angeles) Transplant and Liver Cancer CentersDepartment of Surgery David Geffen School of Medicine at University of California, Los Angeles Los Angeles CA Department of Medicine Statistics Core University of California, Los Angeles Los Angeles CA.
Yas Sanaiha
Roland A Hernandez
Holly Wilhalme
Sarah Rudasill
Joseph Hadaya
Joseph DiNorcia
Peyman Benharash
University of California, Los Angeles · USCore Laboratories (United States) · USSwedish Medical Center · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
NCATS NIH HHS UL1 TR001881
6 · The paper itself

Abstract

Although socioeconomic disparities persist both pre- and post-transplantation, the impact of payer status has not been studied at the national level. We examined the association between public insurance coverage and waitlist outcomes among candidates listed for liver transplantation (LT) in the United States. All adults (age ≥18 years) listed for LT between 2002 and 2018 in the United Network for Organ Sharing database were included. The primary outcome was waitlist removal because of death or clinical deterioration. Continuous and categorical variables were compared using the Kruskal-Wallis and chi-square tests, respectively. Fine and Gray competing-risks regression was used to estimate the subdistribution hazard ratios (HRs) for risk factors associated with delisting. Of 131,839 patients listed for LT, 61.2% were covered by private insurance, 22.9% by Medicare, and 15.9% by Medicaid. The 1-year cumulative incidence of delisting was 9.0% (95% confidence interval [CI], 8.3%-9.8%) for patients with private insurance, 10.7% (95% CI, 9.9%-11.6%) for Medicare, and 10.7% (95% CI, 9.8%-11.6%) for Medicaid. In multivariable competing-risks analysis, Medicare (HR, 1.20; 95% CI, 1.17-1.24; P < 0.001) and Medicaid (HR, 1.20; 95% CI, 1.16-1.24; P < 0.001) were independently associated with an increased hazard of death or deterioration compared with private insurance. Additional predictors of delisting included Black race and Hispanic ethnicity, whereas college education and employment were associated with a decreased hazard of delisting. In this study, LT candidates with Medicare or Medicaid had a 20% increased risk of delisting because of death or clinical deterioration compared with those with private insurance. As more patients use public insurance to cover the cost of LT, targeted waitlist management protocols may mitigate the increased risk of delisting in this population.

Indexed as

Liver TransplantationAdolescentAdultAgedHumansInsurance CoverageMedicaidMedicareRetrospective StudiesUnited StatesWaiting Lists

Identifiers

PMID33185336
PMCPMC8281984
OpenAlexW3103617042

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.